Sign In
Buy CRSP
$52.08
+0.0600 (+0.115%)
At Close: Jun 03, 2026
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
10:51am, Tuesday, 23'rd Jul 2024
On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.
3 Gene Editing Stocks Shaping the Future of Medicine
04:45pm, Monday, 22'nd Jul 2024
Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby ope
3 Monster Stocks in the Making to Buy Right Now
06:00am, Saturday, 20'th Jul 2024
CRISPR Therapeutics now has its first product on the market. Zealand Pharma has two promising candidates targeting the huge obesity and MASH/NASH markets.
3 Gene Editing Stocks That Could Grow Your Wealth
01:30pm, Wednesday, 17'th Jul 2024
Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.
3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition
11:30am, Wednesday, 17'th Jul 2024
Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology. Examples include CRISPR and other gene-editing technologies.
Add These 5 Hot Biotech Stocks In July
09:22am, Wednesday, 17'th Jul 2024
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing
CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?
07:11am, Wednesday, 17'th Jul 2024
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?
04:15am, Tuesday, 16'th Jul 2024
CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a billion-dolla
1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid
08:45am, Thursday, 11'th Jul 2024
CRISPR Therapeutics could ride the wave of its first approval to deliver solid performance over the long run. Despite decent clinical progress, Ocugen remains a high-risk play that has yet to show its
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
07:12am, Thursday, 11'th Jul 2024
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps i
Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today
07:06pm, Wednesday, 10'th Jul 2024
CRISPR Therapeutics AG (CRSP) closed at $55.56 in the latest trading session, marking a +0.96% move from the prior day.
3 Profitable CRISPR Stocks Earning Analysts' Praise
07:59am, Tuesday, 09'th Jul 2024
CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organism
7 Growth Stocks to Invest $500 In and Cash Out $100K by 2030
07:30am, Tuesday, 09'th Jul 2024
Growth stocks have been driving the market for most of its history, but the trends have only accelerated recently. Investors are willing to slap a higher and higher premium on these growth stocks as l
The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024
07:00am, Tuesday, 09'th Jul 2024
Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for underval
Crispr Therapeutics: Beaten Down But Not Broken
08:30am, Sunday, 07'th Jul 2024
CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in th
